Niclosamide Enhances Cetuximab Efficacy in EGFR-Pathway Wildtype Colorectal Cancer: An Organoid-Based Study
Cancers · 20.11.2026 · 18 (22) · 3711
DOI: 10.3390/cancers18223711 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 20.11.2026. Verfasst von Martina Taglieri und 10 weiteren Autor:innen. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero Ricerca Corrente.
Abstract (Originalsprache)
Background/Objectives. Cetuximab is combined with chemotherapy to treat metastatic colorectal cancer (CRC) with wildtype KRAS/NRAS. Despite its clinical efficacy, resistance frequently develops through reinforcement or bypass of EGFR-dependent signaling. Drugs targeting complementary pathways may therefore provide an alternative strategy to overcome Cetuximab resistance. Niclosamide is an anti-helminthic drug with anticancer activity that can interfere with mitochondrial function and β-catenin signaling. Here, we investigated the effects of combining Niclosamide with Cetuximab in CRC organoids and explored the metabolic mechanisms underlying their activity.
Methods
Four CRC organoids with wildtype EGFR signaling were used as a 3D model to evaluate Cetuximab and Niclosamide alone or in combination. Drug effects were evaluated according to EGF concentration in time-lapse growth and by flow cytometry. An ASCL2 reporter construct was used to monitor the stem cell population. Mitochondrial and oxidative effects were evaluated by measuring ATP synthesis, oxygen consumption rate (OCR), OxPhos efficiency, lipid peroxidation, and catalase activity. A MEK inhibitor was used to investigate the involvement of the MEK/ERK pathway in the metabolic effects of Cetuximab.
Results
High EGF concentration consistently reduced Cetuximab efficacy. The combination of Cetuximab and Niclosamide enhanced the effects of the individual drugs, and Niclosamide partially compensated for reduced Cetuximab activity in the presence of high EGF. The ASCL2 reporter showed increased signal intensity in the presence of Cetuximab, abrogated by Niclosamide. Cetuximab and Niclosamide both impaired mitochondrial bioenergetics, decreasing OCR and ATP synthesis and increasing lipid oxidative damage, as indicated by malondialdehyde accumulation, despite a concomitant increase in catalase activity. The effects of MEK inhibition closely resembled those of Cetuximab on the same markers.
Conclusions
Our study, based on data from four patient-derived organoids, indicates that Niclosamide enhances the activity of Cetuximab and retains inhibitory effects when Cetuximab effectiveness is reduced by high ligand concentrations. Although the two drugs act through distinct upstream mechanisms, their effects functionally converge on mitochondrial bioenergetic impairment and oxidative stress. The ability of MEK inhibition to phenocopy the metabolic effects of Cetuximab supports a role for EGFR–MEK–ERK signaling in this response. These findings provide a mechanistic rationale for further preclinical evaluation of the Cetuximab–Niclosamide combination in CRC.
Förderung
- Ministero Ricerca Corrente
Zitieren
APA
Taglieri, M., Uras, C. R. M., Balbi, M., Gregorio, L. D., Matis, S., Loiacono, F., Ceresa, D., Ardy, M., Ravera, S., Raffaghello, L., & Benelli, R. (2026). Niclosamide Enhances Cetuximab Efficacy in EGFR-Pathway Wildtype Colorectal Cancer: An Organoid-Based Study. Cancers, 18(22), 3711. https://doi.org/10.3390/cancers18223711
Vancouver
Taglieri M, Uras CRM, Balbi M, Gregorio LD, Matis S, Loiacono F, et al. Niclosamide Enhances Cetuximab Efficacy in EGFR-Pathway Wildtype Colorectal Cancer: An Organoid-Based Study. Cancers. 2026;18(22):3711. doi:10.3390/cancers18223711
BibTeX
@article{Taglieri2026,
author = {Taglieri, Martina and Uras, Chiara Rosa Maria and Balbi, Matilde and Gregorio, Linda Di and Matis, Serena and Loiacono, Fabrizio and Ceresa, Davide and Ardy, Massimo and Ravera, Silvia and Raffaghello, Lizzia and Benelli, Roberto},
title = {Niclosamide Enhances Cetuximab Efficacy in EGFR-Pathway Wildtype Colorectal Cancer: An Organoid-Based Study},
journal = {Cancers},
year = {2026},
volume = {18},
number = {22},
pages = {3711},
doi = {10.3390/cancers18223711}
}
EUVIMED